SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Cough Frequency During Treatment Associated With Baseline Cavitary Volume and Proximity to the Airway in Pulmonary TB.

Proaño, A; Bui, DP; López, JW; Vu, NM; Bravard, MA; Lee, GO; Tracey, BH; Xu, Z; Comina, G; Ticona, E; et al. Proaño, A; Bui, DP; López, JW; Vu, NM; Bravard, MA; Lee, GO; Tracey, BH; Xu, Z; Comina, G; Ticona, E; Mollura, DJ; Friedland, JS; Moore, DAJ; Evans, CA; Caligiuri, P; Gilman, RH; Tuberculosis Working Group in Peru* (2018) Cough Frequency During Treatment Associated With Baseline Cavitary Volume and Proximity to the Airway in Pulmonary TB. Chest, 153 (6). pp. 1358-1367. ISSN 1931-3543 https://doi.org/10.1016/j.chest.2018.03.006
SGUL Authors: Friedland, Jonathan Samuel Kirwan, Daniela Elisa

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (274kB) | Preview
[img]
Preview
PDF (Online Supplement) Published Version
Available under License Creative Commons Attribution.

Download (773kB) | Preview

Abstract

BACKGROUND: Cough frequency, and its duration, is a biomarker that can be used in low-resource settings without the need of laboratory culture and has been associated with transmission and treatment response. Radiologic characteristics associated with increased cough frequency may be important in understanding transmission. The relationship between cough frequency and cavitary lung disease has not been studied. METHODS: We analyzed data in 41 adults who were HIV negative and had culture-confirmed, drug-susceptible pulmonary TB throughout treatment. Cough recordings were based on the Cayetano Cough Monitor, and sputum samples were evaluated using microscopic observation drug susceptibility broth culture; among culture-positive samples, bacillary burden was assessed by means of time to positivity. CT scans were analyzed by a US-board-certified radiologist and a computer-automated algorithm. The algorithm evaluated cavity volume and cavitary proximity to the airway. CT scans were obtained within 1 month of treatment initiation. We compared small cavities (≤ 7 mL) and large cavities (> 7 mL) and cavities located closer to (≤ 10 mm) and farther from (> 10 mm) the airway to cough frequency and cough cessation until treatment day 60. RESULTS: Cough frequency during treatment was twofold higher in participants with large cavity volumes (rate ratio [RR], 1.98; P = .01) and cavities located closer to the airway (RR, 2.44; P = .001). Comparably, cough ceased three times faster in participants with smaller cavities (adjusted hazard ratio [HR], 2.89; P = .06) and those farther from the airway (adjusted HR, 3.61;, P = .02). Similar results were found for bacillary burden and culture conversion during treatment. CONCLUSIONS: Cough frequency during treatment is greater and lasts longer in patients with larger cavities, especially those closer to the airway.

Item Type: Article
Additional Information: Copyright © 2018 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: CT, cough, mycobacteria, tuberculosis, Adult, Antitubercular Agents, Cough, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Peru, Prospective Studies, Tomography, X-Ray Computed, Tuberculosis, Pulmonary, Young Adult, Tuberculosis Working Group in Peru*, Humans, Tuberculosis, Pulmonary, Cough, Antitubercular Agents, Tomography, X-Ray Computed, Incidence, Follow-Up Studies, Prospective Studies, Adult, Middle Aged, Peru, Female, Male, Young Adult, cough, CT, mycobacteria, tuberculosis, Science & Technology, Life Sciences & Biomedicine, Critical Care Medicine, Respiratory System, General & Internal Medicine, cough, CT, mycobacteria, tuberculosis, DRUG-SUSCEPTIBILITY ASSAY, MULTIDRUG-RESISTANT TUBERCULOSIS, MYCOBACTERIUM-TUBERCULOSIS, MICROSCOPIC-OBSERVATION, COMPUTED-TOMOGRAPHY, CLINICAL-EVALUATION, TREATMENT RESPONSE, CT FINDINGS, TRANSMISSION, INFECTIOUSNESS, 1103 Clinical Sciences, Respiratory System
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Chest
ISSN: 1931-3543
Language: eng
Dates:
DateEvent
June 2018Published
17 March 2018Published Online
1 March 2018Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MR/K007467/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
D43 TW001140FIC NIH HHSUNSPECIFIED
078067/Z/05/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MR/P019978/1Medical Research CouncilUNSPECIFIED
D43 TW010074FIC NIH HHSUNSPECIFIED
D43 TW009349FIC NIH HHSUNSPECIFIED
R25 TW009340FIC NIH HHSUNSPECIFIED
R24 TW007988FIC NIH HHSUNSPECIFIED
R21 AI094143NIAID NIH HHSUNSPECIFIED
D43 TW006581FIC NIH HHSUNSPECIFIED
MR/P019978/2Medical Research CouncilUNSPECIFIED
0539-01-10Grand Challenges Canadahttp://dx.doi.org/10.13039/501100004828
0537-01-10Grand Challenges Canadahttp://dx.doi.org/10.13039/501100004828
105788/Z/14/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
201251/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
W5_PER_CDT1_PRISMAGovernment of Canadahttp://dx.doi.org/10.13039/501100000023
OPP1118545Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
PubMed ID: 29559307
Web of Science ID: WOS:000434249300020
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113337
Publisher's version: https://doi.org/10.1016/j.chest.2018.03.006

Actions (login required)

Edit Item Edit Item